Another phase I clinical trial (NCT04003649) combining IL-13Rα2 CAR-T-cell therapy with or without anti-PD-1 therapy, nivolumab, and anti-CTLA-4 therapy, ipilimumab, is underway, highlighting the potential for GBM treatment via this new combination treatment strategy. This evidence concerns the gene IL13RA2 and glioblastoma.